Current Report Filing (8-k)
November 09 2021 - 5:19PM
Edgar (US Regulatory)
0000910267
false
0000910267
2021-11-08
2021-11-08
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
November 8, 2021
Titan
Pharmaceuticals, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
001-13341
|
94-3171940
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
400
Oyster Point Blvd., Suite 505, South
San Francisco, CA 94080
(Address of principal
executive offices and zip code)
650-244-4990
(Registrant's telephone
number including area code)
(Registrant's former
name or former address, if changed since last report)
Title of each class
|
Trading Symbol
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value
|
TTNP
|
Nasdaq Capital Market
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01. Regulation FD Disclosure
On November 8, 2021, Titan Pharmaceuticals, Inc.
(the “Company”) announced that additional positive data from an ongoing in vivo study of its human kappa-opioid receptor
agonist (“TP-2021”) ProNeura®-based implant in an established 5'-guanidinonaltrindole (5'-GNTI) itch-induced mouse model
had been reported in a presentation given earlier in the day at the Society for Neuroscience 2021 Meeting.
A copy of the slide presentation, which will be
posted on the Company’s website, is attached hereto as Exhibit 99.1 and incorporated herein by reference. The presentation is being
furnished pursuant to Item 7.01 of this Current Report and shall not be deemed "filed" for the purposes of Section 18 of the
Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. This information shall not be
incorporated by reference into any registration statement pursuant to the Securities Act of 1933, as amended.
Item 8.01. Other Events.
On November 8, 2021, the Company announced the
presentation of data from an ongoing in vivo study of its TP-2021 ProNeura®-based implant. A copy of the press release is attached
hereto as Exhibit 99.2 and incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is filed herewith:
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 9, 2021
|
TITAN PHARMACEUTICALS, INC.
|
|
|
|
By:
|
/s/ Kate Beebe DeVarney, Ph.D.
|
|
Name:
|
Kate Beebe DeVarney, Ph.D.
|
|
Title:
|
President and Chief Operating Officer
|
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Sep 2023 to Sep 2024